Equities

BioXcel Therapeutics Inc

BioXcel Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.665
  • Today's Change-0.055 / -7.61%
  • Shares traded762.34k
  • 1 Year change-87.14%
  • Beta0.2364
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy1
Outperform3
Hold2
Sell0
Strong Sell0

Share price forecast in USD

The 6 analysts offering 12 month price targets for BioXcel Therapeutics Inc have a median target of 6.00, with a high estimate of 18.00 and a low estimate of 1.00. The median estimate represents a 802.26% increase from the last price of 0.665.
High2,606.8%18.00
Med802.3%6.00
Low50.4%1.00

Earnings history & estimates in USD

On Aug 06, 2024, BioXcel Therapeutics Inc reported 2nd quarter 2024 losses of -0.21 per share. This result exceeded the -0.71 consensus loss of the 5 analysts covering the company and exceeded last year's 2nd quarter results by 88.52%.
The next earnings announcement is expected on Nov 14, 2024.
Average growth rate+30.80%
BioXcel Therapeutics Inc reported annual 2023 losses of -6.15 per share on Mar 12, 2024.
Average growth rate-36.14%
More ▼

Revenue history & estimates in USD

BioXcel Therapeutics, Inc. had 2nd quarter 2024 revenues of 1.10m. This bettered the 759.00k consensus of the 5 analysts covering the company. This was 435.92% above the prior year's 2nd quarter results.
Average growth rate+32.34%
BioXcel Therapeutics, Inc. had revenues for the full year 2023 of 1.38m. This was 268.00% above the prior year's results.
Average growth rate+89.33%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.